Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Ovarian Neoplasms

  Free Subscription

Articles published in Ann Oncol

Retrieve available abstracts of 26 articles:
HTML format

Single Articles

    August 2021
  1. MARTIN JE, Khalife-Hachem S, Grinda T, Kfoury M, et al
    Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.
    Ann Oncol. 2021;32:1046-1048.

    July 2021
  2. COLOMBO N, Ledermann JA
    Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines.
    Ann Oncol. 2021 Jul 14. pii: S0923-7534(21)02182.

  3. DI VINCENZO A, Andrisani A, Vettor R, Rossato M, et al
    Estrogen and COVID-19: friend or foe?
    Ann Oncol. 2021;32:933-934.

    June 2021
  4. MIRZA MR, Coleman RL, Gonzalez-Martin A, Moore KN, et al
    Corrigendum to 'The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148-1159].
    Ann Oncol. 2021 Jun 2. pii: S0923-7534(21)02020.

    March 2021
  5. BAERT T, Ferrero A, Sehouli J, O Donnell DM, et al
    The Systemic Treatment of Recurrent Ovarian Cancer revisited.
    Ann Oncol. 2021 Mar 3. pii: S0923-7534(21)00155.
    PubMed     Abstract available

  6. MOORE KN, Oza AM, Colombo N, Oaknin A, et al
    Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
    Ann Oncol. 2021 Mar 2. pii: S0923-7534(21)00157.
    PubMed     Abstract available

    January 2021
  7. MONTOPOLI M, Zorzi M, Cocetta V, Prayer-Galetti T, et al
    Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy.
    Ann Oncol. 2021 Jan 29. pii: S0923-7534(21)00097.

  8. WU XH, Zhu JQ, Yin RT, Yang JX, et al
    Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase 3 trial.
    Ann Oncol. 2021 Jan 13. pii: S0923-7534(21)00008.
    PubMed     Abstract available

  9. TOBALINA L, Armenia J, Irving E, O'Connor MJ, et al
    A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
    Ann Oncol. 2021;32:103-112.
    PubMed     Abstract available

    December 2020
  10. PILIE PG, George A, Yap TA
    Patient selection biomarker strategies for PARP inhibitor therapy.
    Ann Oncol. 2020;31:1603-1605.

    September 2020
  11. MILLER RE, Leary A, Scott CL, Serra V, et al
    ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
    Ann Oncol. 2020 Sep 28. pii: S0923-7534(20)42164.
    PubMed     Abstract available

    June 2020
  12. MIRZA MR, Coleman RL, Gonzalez-Martin A, Moore KN, et al
    The forefront of ovarian cancer therapy: update on PARP inhibitors.
    Ann Oncol. 2020 Jun 19. pii: S0923-7534(20)39891.
    PubMed     Abstract available

    May 2020
  13. MILLSTEIN J, Budden T, Goode EL, Anglesio MS, et al
    Prognostic gene expression signature for high-grade serous ovarian cancer.
    Ann Oncol. 2020 May 27. pii: S0923-7534(20)39841.
    PubMed     Abstract available

    February 2020
  14. WAKS AG, Cohen O, Kochupurakkal B, Kim D, et al
    Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36055.
    PubMed     Abstract available

    July 2019
  15. MATULONIS UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, et al
    Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
    Ann Oncol. 2019;30:1080-1087.
    PubMed     Abstract available

  16. GAILLARD SL, Coleman RL
    Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?
    Ann Oncol. 2019;30:1025-1028.

    May 2019
  17. JOLY F, Ahmed-Lecheheb D, Kalbacher E, Heutte N, et al
    Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.
    Ann Oncol. 2019;30:845-852.
    PubMed     Abstract available

  18. BUECHEL M, Herzog TJ, Westin SN, Coleman RL, et al
    Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.
    Ann Oncol. 2019;30:721-732.
    PubMed     Abstract available

  19. COLOMBO N, Sessa C, du Bois A, Ledermann J, et al
    ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
    Ann Oncol. 2019;30:672-705.
    PubMed     Abstract available

    April 2019
  20. LORUSSO D, Pignata S, Gonzalez-Martin A
    Chemotherapy-free treatments: are we ready for prime time?
    Ann Oncol. 2019;30:497-498.

  21. LIU JF, Barry WT, Birrer M, Lee JM, et al
    Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
    Ann Oncol. 2019;30:551-557.
    PubMed     Abstract available

    February 2019
  22. HUANG T, Tworoger SS, Willett WC, Stampfer MJ, et al
    Associations of early life and adulthood adiposity with risk of epithelial ovarian cancer.
    Ann Oncol. 2019;30:303-309.
    PubMed     Abstract available

  23. TRIFANESCU OG, Topliceanu F, Gusoiu BA, Gales LN, et al
    Reactive oxygen species and vascular endothelial growth factor (VEGF) in ovarian cancer patients.
    Ann Oncol. 2019;30 Suppl 1:i8-i9.

  24. STONE A, Gebski V, Davidson R, Bloomfield R, et al
    Exaggeration of PFS by blinded, independent, central review (BICR).
    Ann Oncol. 2019;30:332-338.
    PubMed     Abstract available

    July 2018
  25. BASU B, Krebs MG, Sundar R, Wilson RH, et al
    Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.
    Ann Oncol. 2018 Jul 17. pii: 5055047. doi: 10.1093.
    PubMed     Abstract available

    February 2018
  26. BIRKBAK NJ, Li Y, Pathania S, Greene-Colozzi A, et al
    Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple negative breast and serous ovarian cancers.
    Ann Oncol. 2018 Feb 14. pii: 4857262. doi: 10.1093.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.